It’s been mostly a downbeat week on the stem cell news front including a deep revisit by Reuters to the Piero Anversa case that has new revelations. It’s ugly stuff involving other folks too. We’ll start on the iPS cell front, where a trial participant had a teratoma. I’ve had a long-standing interest in the …
What are you reading these days and does it include topics like cell therapies for COVID-19, ALS, regenerative potential of fibroblasts, and why Zoom meetings are so tiring for the brain? I cover those topics and more below with recommended reads including papers and media items. Here’s last week’s recommended reads. Here’s to fibroblasts, which …
Weekend recommended reads: Athersys, ALS, COVID-19, Fibroblasts, Zoom brain Read More »
Could two stem cell biotechs Athersys and Mesoblast help in the battle against the novel coronavirus disease COVID-19? Stem cells, ARDS, and COVID-19 I’ve already written two pieces about the idea of using stem cells to battle COVID-19 (here and here), the sometimes fatal disease that arises from infection with the novel coronavirus. Older patients …
There has been a lot of excitement this week about a press release from stem cell biotech Athersys that reported that treatment of stroke patients with its product MultiStem was associated with a statistically significant improvement at 1-year. This sounds encouraging and the stock has spiked up as a result. However, there are some naysayers …
About that Athersys stem cell stroke clinic trial PR… Read More »
Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they …
2023 stem cell & regenerative medicine predictions Read More »
Stem cell stroke therapy research has generated buzz over the years. The goal of today’s post is to fact-check claims about supposed stem cell stroke therapies and educate readers on where clinical research stands. There is some real hope here in the long run, but things have been greatly exaggerated at times. Some clinics are …
Fact-checking stem cell stroke therapy: hope but not there yet Read More »
Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell …
24 cell therapy & stem cell stocks I’m following Read More »
The COVID-19 pandemic is tearing through the country right as we are starting into the holiday season, but the wheels of science including cell biology keep going and we keep reading all the great work. What news or papers caught your eye? Here are some of the things I have on my list of reading. …
Weekend cell biology reads: Mesoblast COVID-19 deal, pubs Read More »
Many are jumping on the bandwagon of trying stem cells for COVID-19 or testing other cellular therapies for the novel coronavirus disease, but there have been problems with either the rationales for the trials themselves or more often with how they portrayed. Sometimes there has even been outright hype. I’ve called this collective trend of …
Overselling stem cells for COVID-19: WSJ article & UMN PR Read More »
Katie Thomas at the New York Times reports that BARDA has dropped considering funding applications for stem cells for COVID-19. The move is part of a larger shift in funding priorities away from lung treatments and toward vaccine development. The decision has puzzled and even angered some stem cell firms and researchers. BARDA stands for …
BARDA drops funding of research into stem cells for COVID-19 Read More »